Showing 1–12 of 175 resultsSorted by latest
Healthcare
CrispIdea’s Healthcare Equity Reports provide in-depth analysis of key subsectors, including Pharma & Biotech, Medical Devices & Equipements, Health Care Plans and HCIT. Our insightful analysis covers stock ratings and recommendations, target price, investment thesis, peer comparisons, financial performance evaluations with valuation and ratio analysis, and management commentary. Stay ahead with CrispIdea, your trusted resource for informed investment decisions in the rapidly evolving healthcare landscape.
Gross margin increased to 83.5%, helped by better production costs and product mix, though partly reduced by lower prices.
Boston Scientific (BSX) is focused on expanding its global manufacturing footprint, with notable investments in the U.S., including a new site in Georgia and increased capacity in Minnesota to support long-term growth.
Stryker reported strong organic sales growth of 10.1% in Q1 2025, led by double-digit growth in MedSurg and neurotechnology, and high single-digit growth in ortho paedics, despite one fewer selling day and a tough 10% year-over-year comparison.
ABT acknowledges that the evolving global economic environment, influenced by new tariff policies, presents a challenge.
GE HealthCare Technologies (GEHC) reported revenue of $4.8 billion in Q1 FY25, up 3% on a reported basis and 4% organically year-over-year, with growth across all segments and strong performance in the U.S.
In the first quarter of 2025, Intuitive Surgical Inc. (ISRG) reported strong operational and financial performance.
n Q1, Roche (ROG) Pharma delivered CHF 11.9 billion in sales, with an 8% growth at constant exchange rates. The US, Europe, and international markets all showed strong growth, with Japan returning to growth as well. Pharma volumes increased by 13%.
In MedTech, sales grew 4.1%, driven by strong results from Abiomed, Shockwave, surgical vision, and wound closure. Important milestones included the upgrade of Impella’s clinical guidelines and the launch of
Shockwave’s new device for peripheral artery disease
The Chemical and Advanced Materials segment saw a 2% decline, mainly due to a high-teens drop in China related to Lunar New Year timing. Diagnostics and Clinical grew 7%, driven by strong results in the Americas and Europe.
Medtronic (MDT) reported its ninth straight quarter of mid-single-digit revenue growth, with strong results across several key areas. Cardiac Ablation Solutions grew 22%, driven by strong demand for its Pulse Field
Ablation (PFA) products.
In fiscal 2025, Veeva’s total revenue grew 16% to $2.747 billion, with subscription revenue increasing 20% to $2.285 billion.
RPRX delivered strong performance in 2024, reporting Portfolio Receipts of $2.8 billion, which was at the high end of its guidance range.